Regenxbio Shares Plunge 37.8% to $6.25 After RGX-202 Trial Data Release
Regenxbio shares plunged 37.8% to $6.25 following release of RGX-202 gene therapy clinical trial data that disappointed investors. Trading volume surged to nearly 10 million shares, reflecting heavy selling pressure as shares neared a day low of $6.02.
1. RGX-202 Trial Data Disappoints Investors
Regenxbio released clinical trial data for its RGX-202 gene therapy candidate, prompting investors to sell heavily and driving the share price down 37.8% to $6.25 in a single session, with a day low of $6.02.
2. Heavy Trading Volume Signals Strong Selling Pressure
Trading volume for Regenxbio surged to nearly 10 million shares, underscoring intense selling pressure and negative sentiment as market participants reacted to the disappointing RGX-202 trial update.
Related News
ICFI
ICF Launches AI Accelerator with Salesforce and Docusign for Licensing, Permitting, Inspections
ICFI•
RLX
RLX Technology Q1 Revenue Nearly Doubles to RMB1.59 Billion with 31.8% Margin
RLX•
AMZN
Amazon MGM Invests $75M in Melania Documentary Despite Political Scrutiny
AMZN•
ALSN
Allison Transmission Wins Penske Best Supplier Award and Highlights Next-Gen 9-Speed
ALSN•
ATLC
Atlanticus Approves $0.476563 Series B Preferred Dividend Payable June 15
ATLC•
Sources
F